Québec is the first province to list OKEDI on the public drug reimbursement formulary for the treatment of schizophrenia

Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), announces the listing of PrOKEDI® (extended-release injectable suspension of risperidone) 75 mg and 100 mg strengths to the drug formulary of the Régie de l'assurance maladie du Québec (RAMQ) effective...